The FDA said it needs three more months to consider Biogen Idec’s Plegridy, an injectable multiple sclerosis treatment, delaying an expected midyear launch for the company’s latest entrant in its blockbuster MS franchise.

…read more

Source: Biogen hits an FDA speed bump with its next-gen MS drug


0 No comments